Non-invasive monitoring of patients hospitalized with heart failure
Studies a non-invasive device that records body signals in adults hospitalized with heart failure.
Plain-language title generated from the registry record
Registry title: Non-Invasive Hemodynamic Monitoring in Hospitalized Heart Failure
Key facts
- Where
- Lund, SwedenSee the site
Where in Sweden
- Skåne University HospitalLund, SwedenTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Acorai AB
- Trial code
- NCT07671742
- Record updated
- 26 June 2026
- Original description
Heart failure hospitalization is associated with a high risk of early readmission and mortality. There is an unmet clinical need for low-burden, non-invasive methods to better understand congestion and hemodynamic status during hospitalization.Read full original descriptionShow less
Hemodynamic Observational Study in Patients With Heart Failure Using a Non-Invasive Multi-Modal Sensing Device (HOSP-HF)
Heart failure hospitalization is associated with a high risk of early readmission and mortality. There is an unmet clinical need for low-burden, non-invasive methods to better understand congestion and hemodynamic status during hospitalization.
This observational study evaluates the association between non-invasive measurements obtained with the Acorai Device 1.0 and clinical data collected during hospitalization and up to 90 days after discharge in patients admitted with heart failure. The device performs short, non-invasive recordings that collect physiological signals from the thoracic region without influencing clinical care.
Participants will undergo daily recordings during hospitalization. Clinical information and outcomes, including heart failure hospitalization and all-cause mortality within 90 days after discharge, will be collected from medical records. The study aims to explore relationships between non-invasive sensor measurements and clinical outcomes in hospitalized heart failure patients.
Inclusion: Age ≥18 years; Hospitalization for primary heart failure, defined as new or worsening heart failure symptoms with objective evidence of congestion requiring initiation or intensification of heart failure-specific therapy; Ability to provide written informed consent.
Exclusion: Any other condition that, in the opinion of the investigator, would preclude the subject from participating in the study or may affect the integrity of the data; Any discretionary exclusion where the inclusion of the subject is deemed to pose potential risks to the subject's well-being or is likely to comprise the compliant performance of the study; Pregnancy or lactation (as confirmed by self-report or medical documentation); Presence of a skin rash or open wound in the area where the Acorai Device model 1.0 will be applied.